Medical Devices APAC

APAC Molecular Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.95 Bn Placeholder estimate
Estimate 2025 $6.62 Bn 21.9% of the global market
Projected 2034 $17.20 Bn 160% Adds $10.59 Bn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 61% of 193 Medical Devices markets here
Key players 6 +1
  • APAC is 21.88% of the global market.
  • Among regions, the largest is North America at $16.35 Bn.
  • Fastest growing: Middle East at 11.3% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$10.59 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Molecular Diagnostics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.95 Bn — —
2025 (base) $6.62 Bn +$666.5 Mn —
2026 (forecast) $7.36 Bn +$741.2 Mn +11.2%
2027 (forecast) $8.18 Bn +$824.2 Mn +23.7%
2028 (forecast) $9.10 Bn +$916.5 Mn +37.5%
2029 (forecast) $10.12 Bn +$1.02 Bn +52.9%
2030 (forecast) $11.25 Bn +$1.13 Bn +70%
2031 (forecast) $12.51 Bn +$1.26 Bn +89.1%
2032 (forecast) $13.91 Bn +$1.40 Bn +110.2%
2033 (forecast) $15.47 Bn +$1.56 Bn +133.8%
2034 (forecast) $17.20 Bn +$1.73 Bn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Molecular Diagnostics Market Analysis at a glance
Market size, 2025$6.62 Bn placeholder estimate
Forecast, 2034$17.20 Bn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, application and end user (see all)
Key playersRoche, Abbott Laboratories, Thermo Fisher Scientific Inc., Qiagen N.V., Hologic, Inc. and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Molecular Diagnostics Market Analysis Executive Summary

Molecular diagnostics tests read DNA, RNA and proteins to find infections, cancer and inherited disease.

Key segments of the molecular diagnostics market include technology (PCR, Sequencing and Isothermal Amplification) and application (Infectious Disease, Oncology and Genetic Disease).

Bar chart: Asia Pacific Molecular Diagnostics market size, 2024–2034, placeholder estimates. $5.95 Bn in 2024, $6.62 Bn in 2025 and $17.20 Bn in 2034, 11.2% CAGR.
Asia Pacific Molecular Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Molecular Diagnostics Market Dynamics

Market Growth Drivers

Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the molecular diagnostics market.

Opportunity

Automation, smaller and cheaper instruments and growth in cancer and genetic testing give the molecular diagnostics market room to grow.

Market Restraints

Costly instruments, a shortage of skilled lab staff and uneven payment for new tests hold back the molecular diagnostics market.

Competitive Landscape for Molecular Diagnostics Market in APAC

The molecular diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Molecular Diagnostics Market in APAC

Molecular Diagnostics in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], Ministry of Health (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Ministry of Health (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Ministry of Health of Indonesia. Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Ministry of Health of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how molecular diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Public data, with sources

Molecular Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Molecular Diagnostics market in Asia Pacific?
Placeholder estimate: about $6.62 Bn in 2025, rising to about $17.20 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Molecular Diagnostics market in Asia Pacific growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Molecular Diagnostics market report cover?
The report splits the market by technology (PCR, Sequencing, Isothermal Amplification, Microarrays and more), application (Infectious Disease, Oncology, Genetic Disease, Blood Screening) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Molecular Diagnostics market?
Key players include Roche, Abbott Laboratories, Thermo Fisher Scientific Inc., Qiagen N.V., Hologic, Inc. and Danaher Corporation.
What is driving the Molecular Diagnostics market?
Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the molecular diagnostics market.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diagnostics and lab testing and genomics

See the topic